Peter S. Heeger
Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai · Icahn School of Medicine at Mount Sinai, Recanati Miller Transplant Institute · Icahn School of Medicine at Mount Sinai
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter S. Heeger as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06919003 · Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)National Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Kidney Transplant
- Ph2NCT05917522 · Assessment of Biomarker-Guided CNI Substitution In Kidney TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · recruiting · Kidney Transplant
- Ph2NCT05518487 · COVID Protection After Transplant - Sanofi GSK (CPAT-SG) StudyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · COVID-19, Kidney Transplant
- Ph2NCT05077254 · COVID Protection After Transplant-Immunosuppression ReductionNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Transplant Recipients, Liver Transplant Recipients · study chair
- Ph2NCT02495077 · Effects of Inhibiting Early Inflammation in Kidney Transplant PatientsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Transplant · principal investigator
- N/ANCT02255123 · Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 StudyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Cardiac Transplantation
- N/ANCT01974999 · A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 StudyNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Disease, Kidney Failure, End Stage Renal Disease
- Ph2NCT01919346 · Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney TransplantationHeeger, Peter, M.D. · terminated · Delayed Graft Function, Kidney Transplantation, Complement Activity
- Ph2NCT01769443 · Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Primary Heart Transplant, Heart Transplantation, Heart Transplant · principal investigator
- Ph2NCT01517984 · Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney TransplantationNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Kidney Transplant Recipients · principal investigator
- N/ANCT00466804 · Noninvasive Methods to Monitor Graft Survival in Heart Transplant PatientsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Heart Transplant · principal investigator
- N/ANCT00308802 · Noninvasive Methods to Monitor Graft Survival in Kidney Transplant PatientsNational Institute of Allergy and Infectious Diseases (NIAID) · completed · Kidney Transplantation · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Assessment of Biomarker Guided CNI Substitution in Kidney TransplantationU01AI170424 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 2022 to 2026 · $50,000 awarded in 2026Same name and institution; not confirmed by an ID
- Characterization of a LILRB3 SNP cluster in kidney transplant recipients associated with post-transplant renal failureR01DK149129 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2026 · $910,670 awarded in 2026Same name and institution; not confirmed by an ID
- Intra-graft C1 esterase inhibitor therapy for deceased kidney transplantationU01AI184203 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 2025 to 2026 · $2,216,525 awarded in 2026Same name and institution; not confirmed by an ID
- Intra-graft C1 esterase inhibitor therapy for deceased kidney transplantationR01AI184203 · NIAID · CEDARS-SINAI MEDICAL CENTER · fiscal years 2024 · $2,216,525 awarded in 2024Same name and institution; not confirmed by an ID
- Decay Accelerating Factor and B cell ImmunityR01AI141434 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2019 to 2023 · $423,750 awarded in 2023Same name and institution; not confirmed by an ID
- CTOT: Biomarker guided CNI substitution in kidney transplantationU01AI063594 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2004 to 2022 · $43,166 awarded in 2022Grant number is on one of their registry trials
- Cell Death Pathways and Heart Transplant RejectionR01AI132405 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2017 to 2021 · $550,756 awarded in 2021Same name and institution; not confirmed by an ID
- Translational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2008 to 2021 · $379,436 awarded in 2021Same name and institution; not confirmed by an ID
- Decay accelerating factor dependent inhibition of T cell immunityR21AI126009 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2016 to 2017 · $211,875 awarded in 2017Same name and institution; not confirmed by an ID
- Complement & T Cell Medicated Allograft RejectionR01AI071185 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2007 to 2016 · $487,476 awarded in 2016Same name and institution; not confirmed by an ID
- Graft rejection and direct versus indirect recognitionR01AI043578 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 1998 to 2013 · $388,280 awarded in 2013Same name and institution; not confirmed by an ID
- Complement & T Cell Medicated Allograft RejectionR56AI071185 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2012 · $339,000 awarded in 2012Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Expanding HOPE Liver Transplantation: Understanding Opportunistic Infection and Cancer RiskU01AI138897 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV, AARON A TOBIAN · fiscal years 2018 to 2026Named on NCT05077254
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:58 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.J Am Soc Nephrol · 2015175 citationsRCR 6.8
- Peritransplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: Results of two randomized controlled pilot trials.Am J Transplant · 202055 citationsRCR 2.8
- Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial.J Am Soc Nephrol · 202327 citationsRCR 2.6
- Heterogeneous alterations in human alloimmunity associated with immunization.Transplantation · 200517 citationsRCR 0.4
- 15 citationsRCR 0.6
- CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients.Am J Transplant · 202213 citationsRCR 1.4
- 9 citationsRCR 3.0
- Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients.Am J Transplant · 20207 citationsRCR 0.3
- Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction.Am J Transplant · 20251 citationsRCR 0.5